Brian Skorney

“I guess I also want to push a little bit on the harbor results and how you sort of interpret potential pivotal trial design as you're thinking about structuring that and kind of given the historical context Serafta has had.”

“I was hoping you could help us think through a little more on the sampling impact in the early days of the Alzheimer's agitation launch. Are these free samples at point of care?”

“Actually, I was hoping you could go over some more details around the study design. I sort of heard the highlights of it at the beginning of the call. But how long is the placebo-controlled period?”

“I'm going to be annoying and also ask a little bit on FDA's issues with VISTAs, just given that it seems like a pretty straightforward data set. Can you just very fresh our memories?”

“And it's also related to the communication plan to the street on the regulatory interactions. It's still a huge area of focus with investors. So I'm curious, what's the level of detail that the street can expect around mid-cycle review, labeling discussion, CMC, inspection scheduling, or anything related to that?”